In a review of earlier published results, he showed that FRβ-specific CAR T cells eradicated AML xenografts in mice [56] and summarized studies in which the same FRβ CAR T cells selectively eliminated immunosuppressive FRβ + TAMs, resulting in control of cancer progression in a syngeneic mouse model of an FRβ-negative ovarian cancer. The gene discussed is FOLR2; the disease is acute myeloid leukemia.